Blood test triggers early immunotherapy in bladder cancer trial

NCT ID NCT04138628

Ongoing Disease control Sponsor: Jørgen Bjerggaard Jensen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether starting immunotherapy earlier—based on a blood test that finds tumor DNA—can control bladder cancer that may have spread after the bladder is removed. About 154 adults whose cancer has returned or is at high risk of spreading will receive the treatment. The goal is to see if this approach leads to better outcomes than waiting for tumors to show up on scans.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

infiltrating bladder urothelial carcinoma Neoplasm Metastasis stage IVb bladder cancer urinary bladder cancer urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER BLADDER CANCER, METASTATIC

Contacts and locations

Show contact details

Locations

Aalborg Universitetshospital

Aalborg, 9100, Denmark
Aarhus University Hospital

Aarhus, 8200, Denmark
Herlev Hospital

Herlev, 2730, Denmark
Odense Universitetshospital

Odense, 5000, Denmark
Rigshospitalet

Copenhagen, 2100, Denmark